Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the approval of its core product, sacituzumab tirumotecan (sac-TMT), for a third indication by the National Medical Products Administration. This approval is significant as sac-TMT is the first ADC globally to show an overall survival benefit for advanced NSCLC following progression on EGFR-TKI therapy. The approval is based on a Phase III study demonstrating significant improvements in progression-free and overall survival compared to standard chemotherapy. This development enhances the company’s positioning in the oncology market and offers a new treatment option for patients with limited alternatives.
The most recent analyst rating on (HK:6990) stock is a Hold with a HK$434.36 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development of antibody-drug conjugates (ADCs) for the treatment of advanced solid tumors. Its core product, sacituzumab tirumotecan (sac-TMT), targets cancers such as non-small cell lung cancer (NSCLC), breast cancer, and gastric cancer, with proprietary intellectual property rights.
Average Trading Volume: 810,520
Technical Sentiment Signal: Buy
Current Market Cap: HK$113.9B
For a thorough assessment of 6990 stock, go to TipRanks’ Stock Analysis page.